Large B-cell Lymphoma Clinical Trials in Pittsburgh, Pennsylvania

4 studies are recruiting for large b-cell lymphoma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Pittsburgh, Pennsylvania
    Locations
    65 in total
    Run by
    AstraZeneca

    See if you can join NCT06564038 on ClinicalTrials.gov

  2. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ I…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    West Penn Hospital, Pittsburgh, Pennsylvania
    Locations
    83 in total
    Run by
    Allogene Therapeutics

    See if you can join NCT06500273 on ClinicalTrials.gov

  3. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    West Penn Hospital, Pittsburgh, Pennsylvania
    Locations
    35 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT05826535 on ClinicalTrials.gov

  4. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Allegheny Health Network, Pittsburgh, Pennsylvania
    Locations
    36 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT07188558 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.